BENDECTIN
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jul 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bendectin is an oral extended-release small molecule tablet approved in 1956 by Sanofi for an undisclosed indication. The mechanism of action and pharmacologic class are not publicly specified in available data. This legacy product represents a mature therapeutic with decades of clinical use.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting team focused on lifecycle extension or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate this product offers limited active hiring and career advancement opportunities at present. Roles would focus on maintenance, generic transition planning, and lifecycle management rather than growth or innovation.
Brand ManagerCommercial Operations Manager
Worked on BENDECTIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.